The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...

Recent findings suggest no significant overall survival difference for patients with locally advanced esophageal squamous cell carcinoma who had neoadjuvant vs adjuvant therapy.

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Matteo Carlino, ...

Pembrolizumab showed a 44% pathological complete response rate in dMMR colon cancer patients, with a major pathological response in 57%. Minimal severe side effects were observed, with 8% experiencing ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual disease ...

In a propensity score-matched analysis, adjuvant therapy was significantly associated with a higher risk for all-cause and cancer-specific mortality and disease recurrence compared with neoadjuvant ...

Nisha Mohindra, MD, and Christopher Towe, MD, discuss what early-stage non-small cell lung cancer treatment options have looked like in the past and a more recent treatment option, neoadjuvant therapy ...